NCT03197064View on ClinicalTrials.gov

Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia

PHASE4CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Postoperative Nausea
Interventions
DRUG

Fosaprepitant 150 mg

Antiemetic used to prevent nausea and vomiting after general anesthesia.

Trial Locations (1)

94305

Stanford University Medical Center, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER

NCT03197064 - Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia | Biotech Hunter | Biotech Hunter